研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

初级保健提供者对智力障碍女性推荐和进行宫颈癌筛查的经验:一项定性研究。

Primary Care Providers' Experiences Recommending and Performing Cervical Cancer Screening for Women with Intellectual Disabilities: A Qualitative Study.

发表日期:2024 May 28
作者: Michele S Lee, Arden D Day, Tamsen L Bassford, Monica R Lininger, Julie S Armin, Heather J Williamson
来源: PHYSICAL THERAPY & REHABILITATION JOURNAL

摘要:

与无残疾的女性相比,有智力和发育障碍(I/DD)的女性接受宫颈癌筛查(CCS)的可能性较小。初级保健提供者 (PCP) 在推荐 CCS 方面发挥着关键作用。本研究的目的是确定 PCP 在为患有 I/DD 的女性推荐和实施 CCS 时考虑的因素。采用定性方法,对大多数接受过家庭医学培训的 PCP 进行了深入的半结构化访谈 (N = 13)。通过归纳数据分析,发现大多数 PCP 报告推荐 CCS;然而,执行 CCS 的后续工作各不相同。 PCP 试图将其 CCS 建议与国家指南保持一致,并为家庭和患者提供有关 CCS 的咨询和教育,同时采取个性化的风险收益方法。尽管大多数 PCP 报告缺乏与提供 I/DD 特定护理相关的知识或培训,但 PCP 试图利用类似人群的经验来推荐和执行 CCS。有机会提高与 I/DD 女性进行 CCS 相关的 PCP 知识。© 2024。作者获得美国癌症教育协会独家许可。
Women with intellectual and developmental disabilities (I/DD) are less likely to receive cervical cancer screening (CCS) relative to women without disabilities. Primary care providers (PCPs) play key roles in recommending CCS. The purpose of this study was to identify factors PCPs consider when recommending and performing CCS for women with I/DD. Using a qualitative approach, in-depth semi-structured interviews (N = 13) were conducted with majority family medicine-trained PCPs. Through inductive data analysis, it was found that most PCPs reported recommending CCS; however, follow-through for performing CCS varied. PCPs attempted to align their CCS recommendations with national guidelines and provided counseling and education to families and patients about CCS while taking an individualized risk-benefit approach. Despite most PCPs reporting a lack of knowledge or training related to providing I/DD-specific care, PCPs attempted to draw upon experiences with similar populations to recommend and perform CCS. There is an opportunity to improve knowledge of PCPs related to performing CCS for women with I/DD.© 2024. The Author(s) under exclusive licence to American Association for Cancer Education.